跳到正文
11月3日周二
10月31日周六
10月30日周五
10月29日周四
  1. Orange AI58

    Anthropic 收购由 Cody Tranbarger 一人创立的药企 Mithril Medicine,他本人将加入 Anthropic 团队。Mithril 以单个运营者加一批 Claude 的方式推进 LAMA2-CMD 等 ECM 相关遗传病的双特异性抗体项目,他把这一模式称为 Pipeline-in-a-Person。加入后相关项目将继续推进,他也会尝试同时运行更多研发项目。

    引用Professor Oak@Prof_Oak_

    Surprise 1: Anthropic acquired a one-person biotech . . . Surprise 2: that person is me Surprise 3: I’m here to tell you all about it Yes, this is what you think it is; after 6 yrs of increasingly loose anonymity: the Professor Oak reveal post …and yes, it has gotten so boring around here that I’m literally doxxing myself to spice up the timeline ------- Ok, allow me to introduce myself. My name is Cody Tranbarger. I mostly tweet, but occasionally find time to dabble in drug dev & starting/building biotechs. My past lives span the VC, crossover, startup continuum; Prof Oak has been my way of keeping a digital foot in those worlds, despite having my physical feet planted elsewhere. The past 18 mo, ‘elsewhere’ was Mithril Medicine, a co. I founded to develop bsAbs for LAMA2-CMD & other ECM-related genetic diseases. Mithril was born out of hands-on building with @MikeNGladstone, @JasonPaulRhodes, @LifeSciVC, & team @atlasventure. Somehow, I made enough half-decent calls along the way (even a broken clock is right twice a day, eh?) to convince them Mithril/I warranted a small seed. While I can hardly rationalize such an outrageously cavalier bet, I’m grateful for it, & I'd partner with Atlas again in a heartbeat. In typical AV fashion, Mithril’s primordial form was virtual, decentralized, & ultra-lean. This stage tends to be short-lived, but for Mithril, it worked surprisingly well, for surprisingly long, thanks in part to the rapid maturation of the AI tools I used liberally. Eventually, Mithril became a bit of an experiment itself - to find the upper bound of how far it could scale as a single operator + a bunch of Claude (+ a stellar bench of part-time consultants). In parallel, I started spending time with @nc_frey, @an1lam, & @CoefficientBio team; and promptly experienced, for the 1st time, AI at the frontier. Soon thereafter, Mithril stopped looking like an experiment, & started looking like a preview of an entirely new operating model. From that spark came “Pipeline-in-a-Person.” The idea immediately resonated when we shared it here back in April; and it was central to the shared vision that led to Anthropic’s acquisition of Mithril, & my joining the team. Why join Anthropic? Three reasons. (1) For Mithril, the programs continue, with more resources & infrastructure behind them, and as much Claude as I can put to work. (2) For me, the chance to start several more programs, & find out how many one person can actually run in parallel - an almost unprecedented luxury for a curious drug hunter. (3) For our mission, a path to institutionalize & scale this new way of working, then put it in the hands of all of biopharma, all over the world - which, candidly, I find the most energizing. Will AI x Bio cure diseases? Unequivocally yes, imo… but not by the route that gets the most airtime. Rather than timeline acceleration & compression, I see orchestration & parallelization as today's low-hanging fruit. Most drug hunters see a handful of go/no-go calls in a career, & spend entirely too much of the rest trading emails (my inbox can attest). Give them the bandwidth to run several programs at once, and the time to focus on scientific judgment, and I’m willing to bet they’ll make better calls. And at scale, better calls translate to more drugs, higher hit rates, broader patient impact, & likely, a disease or 10 or 100 cured. I couldn't be more excited to build toward that future @AnthropicAI. Finally, a heartfelt thank you to BioTwitter/X. The end of anonymity is bittersweet, but if anyone’s earned a proper introduction, you all have. It’s difficult to overstate how much this app has done for me: a decade of education, plenty of friends, many job opportunities, several mentors, a few investors, even a co-founder (fmr). It was the generosity of this community that inspired me to start posting 6 years ago, after just as many years lurking. I hope I’ve been able to pay it forward, in my own small way. But, to be clear, Prof Oak isn’t going anywhere. Same beat, same themes, and now, a front-row seat to drug development at the frontier. Stay tuned for dispatches from the trenches; and remember... Gotta Cure 'Em All

10月28日周三
10月27日周二
  1. Techmeme58

    Anthropic IPO 文件披露联合创始人继任计划

    据 Forbes 的 Anna Tong 报道,Anthropic 的 IPO 文件列出了一项不寻常的继任安排:每位联合创始人都有一份保密的、按顺序排列的最多 10 名继任者名单,且需经五位联合创始人批准。Techmeme 该条目正文主要为播客推荐内容,未提供更多细节。

  2. Techmeme58

    Anthropic 的 S-1 文件披露其上市治理结构

    Matt Levine 在 Bloomberg 撰文分析 Anthropic 的 S-1 文件,指出其治理结构既适合一家有使命驱动色彩的小型合作社,又要满足作为上市公司筹集数十亿美元的需要。Techmeme 页面同时列出多档相关播客,包括 Big Technology Podcast 关于 Anthropic S-1 IPO 申报的紧急节目。

10月26日周一
10月23日周五
  1. 宝玉58

    SemiAnalysis 称 Anthropic 正在对 Claude 订阅额度做 A/B 测试,测试组账号的 5 小时额度提高约 20%,每月总量折合 API 价格少约 20%。该测试只影响部分账号,近期 X 上用户反映的 Claude 额度变少与此有关。

    引用SemiAnalysis@SemiAnalysis_

    🚨🚨ALERT: ANTHROPIC IS A/B TESTING USAGE LIMITS Many users on X are reporting LOWER usage limits right now. THEY ARE NOT WRONG. We detected an A/B test going on that DECREASES your monthly API-value by ~20% while INCREASING your 5h usage limits by ~20%. This only affects SOME accounts. (1/2)🧵

10月21日周三
  1. TechCrunch · AI58

    Eric Schmidt 据报持有 Anthropic 约 1% 股份,约为 CEO Dario Amodei 的一半

    据 Bloomberg 报道,前 Google CEO Eric Schmidt 在 2021 年参与 Anthropic A 轮融资后持有约 1% 股份,当时公司估值 4.61 亿美元。这一比例约为联合创始人兼 CEO Dario Amodei 所持 2% 的一半。Anthropic 被普遍预计在年底前上市,若按最高 2 万亿美元估值计算,Schmidt 的净资产最多可增加 200 亿美元。

10月19日周一
10月17日周六
10月15日周四
10月14日周三
10月10日周六
10月9日周五
10月7日周三
9月24日周四